Thymol (Synonyms: IPMP, p-Cymen-3-ol, 2-isopropyl-5-Methylphenol, NSC 11215, NSC 47821, NSC 49142) |
Catalog No.GC38667
One-Click Copy Product Info
|
Thymol is a phenolic compound with multiple pharmacological activities, such as antibacterial, anticancer, antidiabetic, antineurodegenerative and antirheumatic activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 89-83-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Thymol is a phenolic compound with multiple pharmacological activities, such as antibacterial, anticancer, antidiabetic, antineurodegenerative and antirheumatic activities[1]. Thymol is a transient receptor potential ankyrin subtype 1 channel (TRPA1) agonist[2]. Thymol can show significant activity against bacteria, fungi and parasites by destroying microbial cell membranes, inhibiting enzyme activity and interfering with energy metabolism[3].
In vitro, Thymol (0-150μM) treatment of bladder cancer cells (T24, SW780, J82 cells) and non-malignant urothelial cells (SV-HUC-1 cells) for 0-36h inhibited cell viability in a time- and dose-dependent manner and induced cell cycle arrest at the G2/M phase[4]. Thymol (5μM) treatment of A549 cells for 48h inhibited the epithelial-mesenchymal transition and motility of cells[5].
In vivo, oral administration of Thymol (400mg/kg) to treat pleurisy model rats significantly inhibited inflammatory edema and reduced the amount of pleuritic exudate by 34.2%[6]. Thymol (5mg/kg) was treated by intraperitoneal injection in male albino mice and reduced the mitotic index (MI) of mouse bone marrow cells[7].
References:
[1] Aljelehawy Q H A, Mohammadi S, Mohamadian E, et al. Antimicrobial, anticancer, antidiabetic, antineurodegenerative, and antirheumatic activities of thymol: clarification of mechanisms[J]. Micro Nano Bio Aspects, 2023, 2(1): 1-7.
[2] De La Chapa J J, Singha P K, Lee D R, et al. Thymol inhibits oral squamous cell carcinoma growth via mitochondria‐mediated apoptosis[J]. Journal of Oral Pathology & Medicine, 2018, 47(7): 674-682.
[3] Nourbakhsh F, Lotfalizadeh M, Badpeyma M, et al. From plants to antimicrobials: Natural products against bacterial membranes[J]. Phytotherapy Research, 2022, 36(1): 33-52.
[4] Li Y, Wen J, Du C, et al. Thymol inhibits bladder cancer cell proliferation via inducing cell cycle arrest and apoptosis[J]. Biochemical and biophysical research communications, 2017, 491(2): 530-536.
[5] Li T, Shi J, Wang L, et al. Thymol targeting interleukin 4 induced 1 expression reshapes the immune microenvironment to sensitize the immunotherapy in lung adenocarcinoma[J]. MedComm, 2023, 4(5): e355.
[6] Fachini-Queiroz F C, Kummer R, Estevao-Silva C F, et al. Effects of thymol and carvacrol, constituents of Thymus vulgaris L. essential oil, on the inflammatory response[J]. Evidence‐Based Complementary and Alternative Medicine, 2012, 2012(1): 657026.
[7] Abed R M. Cytotoxic, cytogenetics and immunomodulatory effects of thymol from Thymus vulgaris on cancer and normal cell lines in vitro and in vivo[J]. Al-Mustansiriyah J Sci, 2011, 22(4): 41-53.
| Cell experiment [1]: | |
Cell lines | T24, SW780, J82, SV-HUC-1 cells |
Preparation Method | Bladder cancer cells T24, SW780, J82 and non-malignant urothelial cells SV-HUC-1 were treated with different concentrations of Thymol (0, 25, 50, 100, 150μM) for 24h or a certain dose (100μM) of Thymol for different times (0, 6, 12, 24, 36h). Changes in cell viability were measured by MTT assay. |
Reaction Conditions | 0, 25, 50, 100, 150μM; 0, 6, 12, 24, 36h |
Applications | Thymol inhibited bladder cancer cell proliferation in a dose and time-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Wistar rats |
Preparation Method | The animals were orally pretreated with Thymus vulgaris essential oil (TEO) (250, 500, or 750mg/kg), Carvacrol (100, 200, or 400mg/kg), and Thymol (100, 200, or 400mg/kg). Indomethacin (5mg/kg) and Celecoxib (10mg/kg) were used as standard drugs. Control rats received only water. One hour later, all of the animals, with the exception of the normal group, received an intrapleural injection of carrageenan (200μg/animal). Four hours later, the animals were euthanized, and the pleural exudate was collected. |
Dosage form | 100, 200, 400mg/kg; p.o. |
Applications | Thymol significantly reduced the volume of pleural inflammatory exudates by 34.2%, at a dose of 400 mg/kg. |
References: | |
| Cas No. | 89-83-8 | SDF | |
| Synonyms | IPMP, p-Cymen-3-ol, 2-isopropyl-5-Methylphenol, NSC 11215, NSC 47821, NSC 49142 | ||
| Canonical SMILES | OC1=CC(C)=CC=C1C(C)C | ||
| Formula | C10H14O | M.Wt | 150.22 |
| Solubility | DMSO: 125 mg/mL (832.11 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.6569 mL | 33.2845 mL | 66.569 mL |
| 5 mM | 1.3314 mL | 6.6569 mL | 13.3138 mL |
| 10 mM | 665.7 μL | 3.3285 mL | 6.6569 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)